Enanta’s NS5A inhibitor (EDP-239) was announced 2 years ago (#msg-47301187), and there was nary a peep about it until now. NVS’ back-ended deal looks much more reasonable than what other HCV suitors have been doing lately.
Enanta is also the developer of ABT’s ABT-450 PI (#msg-61757048).
Market Data 
Markets 
AI
